Effect of the incrnetn mimnetc liraglutide (victoza) on body weight and glycated hemoglobin levels in patients with type 2 diabetes mellitus in diabetology offices in Czech Republic: The BIVI study;Vliv inkrnetnového mimnetka liraglutidu(victoza) na hmotnost a hladiny glykovaného hemoglobinu u nemocných s diabetes mellitus2. typu v diabetologických ordinacích čr -studie bivi

Interni Medicina pro Praxi

Volumn 15, Issue 5, 2013, Pages 170-175

  Perušičová, Jindřiška ^a   Skupina, Pavlína Pithová a pracovní ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

BMI; HbA1c; Liraglutid

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE;

ARTICLE; BODY MASS; BODY WEIGHT; CZECH REPUBLIC; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; WAIST CIRCUMFERENCE;

EID: 84884323872     PISSN: 12127299     EISSN: 18035256     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Blevins T, Han J, Nicewarner D, Chen S, Oliveira JH, Aronoff S. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med 2010; 122: 118-128.
2. Buse JB, Rosenstock J, Sesti G et al, LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374 (9683): 39-47.
3. Buse J, Sesti G, Schmidt W, et al. Switching from exenatide to liraglutide increases the proportion of patients achieving A1c targets. Diabetes 2011; 60 (Suppl. 1): A307.
4. Buse JB, Nauck MA, Forst T, et al. Effi cacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Diabetologia 2011; 54 (Suppl. 1): A75.
5. Buse JB, Garber A, Rosenstock J, et al.: Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Eff ect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab 2011; 96: 1695-1702.
6. Courreges JP, Vilsboll T, Zdravkovic M, et al. Benefi cial eff ects of once-daily liraglutide, a human glucagon-like peptide- 1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabet Med 2008; 25: 1129-1131.
7. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment has no eff ect on the effi cacy and safety of liraglutide. Endocr Pract 2010; Dec 6: 1-31.
8. Fonseca V, Madsbad S, Falahati A, Zychma MJ, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic BP - a meta-analysis of 6 clinical trials. Diabetes 2009; 58 (Suppl. 1): A146.
9. Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabnetc drug therapy: onset of treatment eff ects over time. Int J Clin Pract 2010; 64: 267-276.
10. Gough SCL. Liraglutide: from clinical trials to clinical practice. Diabetes Obes Metab 2012; 14 (Suppl. 2): 33-40.
11. Horowitz M, Vilsboll T, Zdravkovic M, Hammer M, Madsbad S. Patient reported rating of gastrointestinal adverse eff ects during treatment of type 2 diabetes with the once- -daily human GLP-1 analogue, liraglutide. Diabetes Obes Metab 2008; 10: 593-596.
12. Jonker D, Toft AD, Kristensen P, Knudsen L, Watson E. Pharmacokinnetc modelling of the once-daily human GLP-1 analogue liraglutide in healthy volunteers and comparison to exenatide. Diabetes 2007; 56 (Suppl. 1): A160.
13. Montanya E, Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009; 31: 2472-2488.
14. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. Diabetes Care 2009; 32: 834-838.
15. Rossi MC, Nicolucci A. Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. Acta Biomed 2009; 80: 93-101
16. Schmidt WE, Christiansen JS, Hammer M, Zychma M, Buse J. Patient reported outcomes are superior in patients with type 2 diabetes (T2D) treated with liraglutide as compared to exenatide, when added to metformin, sulfonylurea or both. Diabetes 2009; 58 (Suppl. 1): A483.